FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	S IN BENEFICIA	AL OWNERSHIP

OMB APPI	ROVAL
B Number:	3235-0287
imated average b	urden
rs per response:	0.5
	B Number:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  KAKKIS EMIL D					2. Issuer Name <b>and</b> Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [ RARE ]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner						
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT				3. Date of Earliest Transaction (Month/Day/Year) 03/01/2020							X	X Officer (give title Other (specify below)  President & CEO			pecify				
(Street)	) C.	A	94949		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)	Form filed by One Reporting Person Form filed by More than One Reporting			1			
(City)	(S	tate)	(Zip)												Person	1			
		Tab	le I - No	n-Deri	vativ	e Se	curities	s Acc	uired,	Dis	posed o	f, or E	enef	icially	Owned				
Date		2. Trans Date (Month/		ar) l	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Securitie Beneficia Owned F	5. Amount of Securities Beneficially Dwned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct of ndirect Ir. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or P	rice	Reported Transaction(s) (Instr. 3 and 4)			(	(Instr. 4)
Common	Stock			03/03	1/2020	0			A		17,000	(1)	<b>A</b>	\$0.00	492,	914(2)	Ι	)	
Common	Stock			03/03	03/01/2020				A		18,782	2 <sup>(3)</sup> A \$		\$0.00	511,	511,696 <sup>(2)</sup>		)	
Common	Stock			03/03	1/2020	0			F 6,8		6,896(	<sup>4)</sup> ]	) !	\$56.08	504,	800(2)		)	
Common Stock														2,559,741		1		By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009	
		-	Table II -												Owned				
Derivative Conversion Date Execusecurity or Exercise (Month/Day/Year) if any		3A. Deeme Execution if any (Month/Day	ed 4. Date, Transactio		5. Number 6		Options, converti 6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		nount	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	i G F lly D o	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisab		Expiration Date	Title	or Nu of	mber ares					
Stock Option (Right to Buy)	\$56.08	03/01/2020			A		56,100		(5)		03/01/2030	Commo Stock		,100	\$0.00	56,100		D	

- 1. Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. Represents 6,198 shares of common stock and 12,584 RSUs which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021.
- 4. Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- 5. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

## Remarks:

/s/ Karah Parschauer, attorneyin-fact

03/03/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.